Friday, September 17, 2010

The FDA is strengthening its labeling about gadolinium based contrast agents

---concerning the risk of nephrogenic systemic fibrosis. Via MedPage Today.

1 comment:

Michael Kirsch, M.D. said...

company in process in Ohio. Of course, we'll await the facts, but we all know the technique of relying upon retrospectocopy after an adverse event has developed can be unfair. I'm not prepared to demonize the industry over allegations, even though many journalists and editors have different standards.